---
title: "Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference"
description: "Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference Nuvectis Pharma Inc. (NASDAQ: NVCT), a clinical-stage biopharmaceutical company, will present at the 3rd Annual H.C. Wa"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/240641875.md"
published_at: "2025-05-16T20:35:13.000Z"
---

# Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference

> Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference Nuvectis Pharma Inc. (NASDAQ: NVCT), a clinical-stage biopharmaceutical company, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. The event is scheduled for May 20th, 2025, from 10:30 to 11:00 a.m. ET. Ron Bentsur, Chairman and CEO, will provide insights into the company's development of innovative precision medicines for oncology.

Nuvectis Pharma Inc. (NASDAQ: NVCT), a clinical-stage biopharmaceutical company, will present at the 3rd Annual H.C. Wainwright Global BioConnect Investor Conference. The event is scheduled for May 20th, 2025, from 10:30 to 11:00 a.m. ET. Ron Bentsur, Chairman and CEO, will provide insights into the company's development of innovative precision medicines for oncology.

### Related Stocks

- [NVCT.US - Nuvectis Pharma](https://longbridge.com/en/quote/NVCT.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Nuvectis Pharma Launches Phase 1b Trial of NXP900 and Osimertinib in EGFRmut+ NSCLC | Nuvectis Pharma Inc. has initiated a Phase 1b clinical trial to evaluate the combination of NXP900 and osimertinib in EG | [Link](https://longbridge.com/en/news/270006176.md) |
| Director Matthew L. Kaplan Acquires Common Shares of Nuvectis Pharma Inc | Matthew L. Kaplan, Director of Nuvectis Pharma Inc., has acquired common shares of the company. The full filing is avail | [Link](https://longbridge.com/en/news/264659938.md) |
| Nuvectis Pharma Hosts Virtual Meeting on NXP900 Phase 1b Program in Advanced Solid Tumors | Nuvectis Pharma Inc. will host a virtual meeting on December 2, 2025, to discuss the NXP900 Phase 1b Program in advanced | [Link](https://longbridge.com/en/news/267359156.md) |
| Nuvectis Pharma FY2029 EPS Forecast Lifted by Roth Capital | Roth Capital has raised its FY2029 earnings forecast for Nuvectis Pharma (NASDAQ: NVCT) from $3.10 to $3.34 per share. T | [Link](https://longbridge.com/en/news/264677828.md) |
| Nuvectis Pharma Insider Bought Shares Worth $957,083, According to a Recent SEC Filing | Nuvectis Pharma Insider Bought Shares Worth $957,083, According to a Recent SEC Filing | [Link](https://longbridge.com/en/news/263285973.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.